Breakthrough in Cancer Gene Therapy: Targeted Nanoliposomes Show Promise

Researchers at the State Research Center, in collaboration with international colleagues, have made a significant contribution to the field of cancer gene therapy. According to a recent study published in Acta Naturae, they have engineered targeted nanoliposomes capable of delivering large quantities of boronophenylalanine into cancer cells. This innovation may lead to the development of more effective boron neutron capture therapy (BNCT) for cancer treatment.

Key Takeaways:

• The study focuses on the engineering of tumor-specific liposomes loaded with 4-L-boronophenylalanine (4-L-10BPA) for application in boron neutron capture therapy.
• The researchers used spectrophotometry and ICP-mass spectroscopy to determine the 4-L-10BPA-to-liposome molar ratio, which was found to be approximately 120,000.
• DARPin-modified liposomes were designed to target human epidermal growth factor receptor 2 (HER2) and were found to effectively bind to HER2-overexpressing cells and be internalized into the cytoplasm.
• The study's results indicate that DARPin-functionalized liposomes can precision-deliver large quantities of 4-L-10BPA into cancer cells, opening up new prospects for BNCT.
• The research has been peer-reviewed and published in Acta Naturae, a reputable scientific journal.

Statistics:

• The 4-L-10BPA-to-liposome molar ratio was found to be approximately 120,000.
• The study's results indicate that DARPin-functionalized liposomes can precision-deliver large quantities of 4-L-10BPA into cancer cells.
• The research has been published in Acta Naturae, a scientific journal with a reputation for publishing high-quality research.
• The study was conducted collaboratively by researchers at the State Research Center and international colleagues.

Sources:

• Acta Naturae, 2025;17(3):88-93.